JPRN-UMIN000011873已完成未知
Phase II study of Efficacy and Safety of SJE-2079 in the Treatment for Diabetic Macular Edema - Efficacy and Safety of SJE-2079 for Diabetic Macular Edema
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Active and serious retinal disease 2)History of steroid-induced elevation of IOP 3)Any active ocular disease other than diabetic retinopathy
研究者
相似试验
已完成
不适用
Phase II study of Efficacy and Safety of SJE-2079 in the Treatment for Diabetic Macular EdemaDiabetic macular edema (DME)JPRN-UMIN000005648Clinical Development Div., Senju Pharmaceutical co.,ltd.150
已完成
不适用
Phase III study of Efficacy and Safety of SJP-0118 in bacterial blepharitis, dacryocystitis or hordeolum/ acute suppurative chalazion.acterial blepharitis, dacryocystitis or hordeolum/ acute suppurative chalazionJPRN-UMIN000019698Senju Pharmaceutical co.,ltd.45
已完成
不适用
Phase III study of Efficacy and Safety of SJP-0118 compared to Vehicle and Levofloxacin in the treatment of bacterial conjunctivitis.Bacterial conjunctivitisJPRN-UMIN000018481Senju Pharmaceutical co.,ltd.500
进行中（未招募）
不适用
A Phase 2 Efficacy And Safety Study Of Su011248 In Patients With Non-Small Cell Lung Cancer And Brain MetastasesEUCTR2006-004451-38-ESPfizer, S.L.U.60
进行中（未招募）
不适用
A Phase 2 Study of the Efficacy and Safety of SU-014813 in Patients with Metastatic Breast Cancer - NDocally Recurrent or Metastatic Breast Cancer MBCMedDRA version: 6.1Level: PTClassification code 10055113EUCTR2005-004941-33-ITPFIZER70